Biopharma industry looks beyond GLP-1s for next-gen weight loss treatments
At the ObesityWeek 2026 conference, biopharma companies are shifting attention beyond standard GLP-1 drugs to explore new pathways like amylin modulation. Industry experts emphasize that the next generation of weight loss therapies will focus heavily on improving treatment persistence and the quality of weight reduction, particularly preserving muscle mass.
Original image temporarily unavailable
Amylin Pipeline Competition
As existing GLP-1 treatments like Wegovy and Zepbound face challenges regarding side effects and plateauing results, amylin analogs are emerging as a primary alternative. Companies such as Novo Nordisk, Eli Lilly, and a partnership between Roche and Zealand Pharma are showcasing data for their pipeline assets, balancing higher efficacy against tolerability trade-offs.
Muscle Preservation and Quality
Beyond raw weight loss numbers, companies are prioritizing body composition. Biohaven and Wave Life Sciences are presenting data on therapies designed to target myostatin and INHBE proteins, aiming to reduce fat while preserving lean muscle, addressing a major drawback of current incretin drugs.
Persistence and Long-Term Value
Industry leaders note that roughly half of patients drop out of treatment within six months. Presentations at the conference, including Rhythm Pharmaceuticals' long-term data, highlight the growing importance of treatment durability and persistence in determining the true commercial and clinical value of obesity therapeutics.
View selection rationale
Importance 83/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- BioSpace Drug Development ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.
